Analytical Tool: The Complete Guide to Leukemia Therapeutics

Published by: BioSeeker Group AB

Published: Oct. 26, 2004

Table of Contents

Competition on the Future Leukemia Markets

BSG General Working Model & Methodology

Acute Lymphoblastic Leukemia & Related Competition

Introduction & Current Treatment Options

Box 1. Major treatment regimes

Next-generation nucleoside antimetabolite

Slow progress for DNA topoisomerase II inhibitor

Novel Ribonucleotide Reductase Inhibitor Moves Clinical

Table 1. Near Term Progress.

Old ribonucleotide reductase inhibitor discontinued

Fast track status on second-generation immunomodulator

Table 2. Near Term Progress

Chronic Lymphocytic Leukemia & Related Competition

Introduction & Current Treatment Options

Box 2. CLL staging system

Box 3 - Updated REAL/WHO Classification for B-Cell Neoplasms

Blockbuster heading for new markets

Table 3. Near Term Progress

Questioned sincerity and reliability by the FDA

Table 4. Near Term Progress

Competitive studies

Box. 4. Large Campath Study Evaluate the Efficacy and Safety of Front-Line Therapy with Alemtuzumab vs. Chlorambucil.

Table 5. Near Term Progress

Clinical studies initiated for apoptotic drug

Discontinuation due to toxicity

Table 6. Near Term Progress

Phase II data on apoptosis inducer

Table 7. Near Term Progress

Acute Myeloid Leukemia & Related Competition

Introduction & Current Treatment Options

Box 5. The general structure for treatment of AML

Continuing efforts on Mylotarg

Table 8. Near Term Progress

A sub-population of the patients are cured

Table 9. Near Term Progress

Initiation of Phase III

Flt3 Ligand

Table 10. Near Term Progress

Moving up to phase II

Targeting intracelluar kinases

Table 11. Near Term Progress

Table 12 Near Term Progress

Is VEGF receptor inhibition the right target?

Table 13. Near Term Progress

Table 14 Near Term Progress

Several DNA targeting drugs in development

Table 15. Near Term Progress

Table 16 Near Term Progress

Cancer Vaccine Struggle

Additional Mab therapy for the treatment of AML?

Multidrug resistance inhibitor

Combination treatment superior

Chronic Myelogenous Leukemia & Related Competition

Introduction & Current Treatment Options

Box 5. CML R&D

Sixty studies presented on Gleevec

Table 17. Near Term Progress.

The Interferons

Table 18. Clinical studies including Interferon for the treatment of leukemia.

Farnesyl transferase inhibitors for the treatment of leukemia

Table 19. Near Term Progress

Overcoming Gleevec resistance?

Table 20. Near Term Progress

Additional strategies

Another blockbuster seeking new markets

Table 21. Near Term Progress

Personalized Vaccine

MDR inhibitor

Inducing apoptosis

Disclaimer

Liability

Completeness

Abstract

Executive Summary

Leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry. This has now clearly changed with the launch of Novartis' second-line therapy Gleevec (imatinib mesylate) for chronic myeloid leukemia (CML), is presenting the industry with proof that development within the leukemia market produces lucrative returns. Gleevec saw sales rise 47 percent to $757 million in the first half 2004. There will soon be a harder competition in several of the leukemic sub-markets and current treatments will be changed for the benefit of more innovative therapies.

Reasons to purchase this Analytical Tool

This is the only product that provides you with a complete structure of the areas involved in analyzing leukemia therapeutics.
Identify and structure most B2B collaborations and industry-academic alliances
It covers close to all areas of therapeutic strategies
You will be able to study areas in conjunction to leukemia structured by therapy type, drug effects, mechanisms/targets and combinatory therapies
To track cutting edge competitive companies, therapies and technologies in the future market
You will save time and money by rapid identification and analysis of competitors and business opportunities.
Evaluate progress in both established as well as novel treatment strategies competing within the field.

BioSeeker Group has identified more than 60 companies and at least 40 different candidate drugs or combinations that have reached Phase II-III. Hundreds of investigational drugs are under development at different stage of development. Our leukemia database includes more than 5000 records from a multitude of information sources.

"Analytical Tool: The Complete Guide to Leukemia Therapeutics" offers a unique tool for analyzing the complex competitive pressure within the different fields of leukemia therapeutics. It is at the same time a map of the research and development, an up to date history of the achievements and a guide pointing out the directions of the future. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. Additionally, BioSeeker Group has developed a CD-ROM searchable database, which is highly updated to reflect the most recent advances in the field, in order to help you perform your own specific analysis, go back to the source data for in-depth information, and to offer you an opportunity to present the R&D in tables and graphs suited for your own specific purposes.

A significant advantage with this CD-ROM's searchable databases is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker Group CD-ROM searchable databases provide you with a better overview and specific search capabilities.

For your convenience, information about new innovative leukemia therapies such as antisense, monoclonal antibodies, gene therapy, antigen- or cellular-based vaccines, liposomal hormones, apoptotic drugs and other small molecular drugs are analyzed in hundreds of extensive tables and graphs. "Analytical Tool: The Complete Guide to Leukemia Therapeutics" offer you easy-to-read tables with projects classified into well-defined structures based on type of therapy given, effect and mechanism. The graphs provide all the relations of these factors as well as the general and specific trends in this competitive landscape. Please see each part of the tool:

This Analytical Tool includes:
Competition on the Future Leukemia Markets
Basic Platform Report: Leukemia Therapeutics
Business Development and R&D Database: Leukemia

"Analytical Tool: The Complete Guide to Leukemia Therapeutics" is based on three major parts:

Analysis
Information Structure
Databases

This Analytical Tool includes:

Information on several hundreds of companies, clinical trials and drugs active in this field
Numerous graphs illustrating the most important relations between cancer types, types of therapy, effects and mechanisms
Advanced analysis of general and specific trends.
Possibility of performing advanced searches suited to your individual needs

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.